Viewing data from:

GEOCILLIN

NDA

CARBENICILLIN INDANYL SODIUM | N050435 | PFIZER LABORATORIES DIV PFIZER INC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain0 active DMFs3 inactive

0 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

PFIZER INCInactiveCARBENICILLIN INDANYL SODIUM

DMF 132901998

PFIZER INCInactiveCARBENICILLIN INDANYL SODIUM

DMF 134001998

SMITHKLINE BEECHAM PHARMACEUTICALSInactiveCARBENICILLIN INDANYL SODIUM

DMF 134471998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Feb 29, 2008	SUPPL -9	View Letter (PDF)
Dec 29, 2004	SUPPL -8	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 382MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.